Search results for "Factor X"

showing 10 items of 80 documents

Interaction between C1-INA, coagulation, fibrinolysis and kinin system in hereditary angioneurotic edema (HANE) and urticaria.

1984

The C1-inactivator plays an important role not only in the initial phases of the complement system, but also in those of the coagulation, fibrinolysis and kinin systems. The present study was concerned with the reciprocal influence of decreased C1-inactivator levels in patients with hereditary angioneurotic edema (HANE, HAE). In 13 HANE-I patients there were significantly increased levels of the coagulation factors XII, XI, V, of plasminogen and of alpha 2-antiplasmin, while the factors IX and VII were decreased. Conversely, it emerged that in patients with markedly raised prephase factor levels, angioneurotic edema occurred in the presence of normal or only slightly decreased C1-inactivato…

medicine.medical_specialtyUrticariaHereditary angioneurotic edemamedicine.medical_treatmentDermatologyKininsComplement C1 Inactivator Proteinschemistry.chemical_compoundInternal medicineEdemaFibrinolysismedicineHumansAngioedemaFactor XIIAngioedemaFactor VIIbusiness.industryFibrinolysisGeneral MedicineKininBlood Coagulation FactorsEndocrinologyCoagulationchemistryImmunologymedicine.symptombusinessArchives of dermatological research
researchProduct

Diagnosis and Treatment of Lower Extremity Venous Thromboembolism

2020

Importance: Incidence rates for lower extremity deep vein thrombosis (DVT) range from 88 to 112 per 100 000 person-years and increase with age. Rates of recurrent VTE range from 20% to 36% during the 10 years after an initial event.Observations: PubMed and Cochrane databases were searched for English-language studies published from January 2015 through June 2020 for randomized clinical trials, meta-analyses, systematic reviews, and observational studies. Risk factors for venous thromboembolism (VTE), such as older age, malignancy (cumulative incidence of 7.4% after a median of 19 months), inflammatory disorders (VTE risk is 4.7% in patients with rheumatoid arthritis and 2.5% in those withou…

medicine.medical_specialtyVena Cava FiltersDeep vein01 natural sciencesPostthrombotic Syndromelaw.inventionFibrin Fibrinogen Degradation Products03 medical and health sciencesSex Factors0302 clinical medicineRandomized controlled trialPredictive Value of TestsRisk FactorslawInternal medicineMedical IllustrationFactor V LeidenHumansThrombophiliaMedicineCumulative incidencecardiovascular diseases030212 general & internal medicine0101 mathematicsLife StyleThrombectomyUltrasonographybusiness.industry010102 general mathematicsAge FactorsWarfarinVenous ThromboembolismGeneral Medicinemedicine.diseaseThrombosisPre- and post-test probabilitymedicine.anatomical_structureLower ExtremityPredictive value of testsWarfarinSymptom AssessmentbusinessBiomarkersFactor Xa Inhibitorsmedicine.drugJAMA
researchProduct

Atrial fibrillation and chronic kidney disease: focus on rivaroxaban

2015

Renal insufficiency increases the risk of stroke and bleeding in atrial fibrillation patients. Although vitamin K antagonists reduce the risk of stroke in patients with moderate renal dysfunction, this observation is less clear in patients with renal impairment. Moreover, the risk of bleeding with vitamin K antagonists increases as renal function worsens. Maintaining international normalized ratio values within therapeutic targets is more difficult in patients with renal dysfunction, and those agents may cause warfarin-related nephropathy and vascular calcification. Rivaroxaban is the only nonvitamin K oral anticoagulant with a dose specifically tested in patients with moderate renal insuff…

medicine.medical_specialtyVitamin Kmedicine.drug_classRenal functionurologic and male genital diseasesNephropathyRivaroxabanInternal medicineAtrial FibrillationmedicineHumansRenal Insufficiency ChronicStrokeAgedRivaroxabanbusiness.industryHealth PolicyWarfarinAnticoagulantsAtrial fibrillationVitamin K antagonistmedicine.diseaseStrokeCardiologyWarfarinbusinessFactor Xa Inhibitorsmedicine.drugKidney diseaseJournal of Comparative Effectiveness Research
researchProduct

Predictive Value for Increased Factor XIa and Plasma Kallikrein Activity in Acute Venous Thromboembolism

2021

Abstract Venous thromboembolism (VTE) is associated with increased coagulation activity, which in part can be attributed to the contact pathway of coagulation. Evidence from pre-clinical and epidemiological studies suggests that deficiency in factors of contact activation (e.g. coagulation factors (F) XI and FXII) protects against VTE. However, limited information exists regarding the activation of the contact system in the setting of acute VTE. In the current study, patients with confirmed VTE events (n=321) from the VTEval study and controls (n=300) from the population-based PREVENT-it pilot study were included. Plasma samples were collected from patients after confirmed VTE events or con…

medicine.medical_specialtybusiness.industryImmunologyFactor XIaCell BiologyHematologyBiochemistryPredictive valuePlasma kallikrein activityInternal medicinemedicineCardiologycardiovascular diseasesbusinessVenous thromboembolismBlood
researchProduct

POST-OPERATIVE CHANGES IN FACTOR XIII and FIBRCNETITN

1987

Wound healing processes after surgery are not restricted to certain areas tut affect the vhole body; the ooagulaticn systan in particular is involved. We studied Factor XIII and fibrcnectin in the blood plasma of 16 patients before surgery, after surgery and cn the 1st, 3rd and 7th days after surgery; fibrcnectin was determined using IC-Partigen iimunodiffusicn and Factor XIII by Behringwerke rapid test. In 11 patients normal wound healing was observed (group A), while in 5 patients explications oocured (group B). Factor XIII: normal group (A): fall in concentration oenpared with the precpera-tive value up to the 7th day after surgery; group with explications (B): fall in concentration more…

medicine.medical_specialtybusiness.industrymedicinePost operativeFactor XIIIbusinessmedicine.drugSurgeryXIth International Congress on Thrombosis and Haemostasis
researchProduct

Tutorial in oral antithrombotic therapy: biology and dental implications.

2013

Objectives: Recent developments of new direct oral anticoagulants that target specific clotting factors necessitate understanding of coagulation biology. The objective of this tutorial is to offer dental professionals a review of coagulation mechanisms and the pharmacodynamics of the conventional and new oral anticoagulants. Also, we summarized the dental implications of the conventional and new anticoagulants. Method: We searched Medline using search terms “antithrombotic”, “antihemostasis” or “anticoagulation” and combined them with the search results of “dental”, “oral surgery” or “periodontal”. We restricted the results to “human” and “English”. Results: The early coagulation cascade, t…

medicine.medical_specialtymedicine.drug_mechanism_of_actionFactor Xa InhibitorOral Surgical ProceduresAdministration OralOdontologíaHemorrhage030204 cardiovascular system & hematologyOral Surgical Procedures03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRisk FactorsAntithromboticmedicineHumansIntensive care medicineGeneral DentistryClotting factorbusiness.industryWarfarinReview-Article030206 dentistryPerioperative:CIENCIAS MÉDICAS [UNESCO]Ciencias de la salud3. Good healthSurgerystomatognathic diseasesOtorhinolaryngologyDirect thrombin inhibitorUNESCO::CIENCIAS MÉDICASSurgeryOral SurgerybusinessFibrinolytic agentmedicine.drugMedicina oral, patologia oral y cirugia bucal
researchProduct

Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials

2018

Abstract Background Prediction models for venous thromboembolism recurrence will likely be improved by adding levels of coagulation factors. Risk assessment is ideally performed during anticoagulant treatment, however, the influence of direct oral anticoagulants on coagulation factors is uncertain. Objective To assess the influence of rivaroxaban and apixaban on several coagulation factor levels. Methods In two crossover trials we assessed the influence of rivaroxaban and apixaban intake on factor (F)VIII, FXI and FXII‐activity and fibrinogen, von Willebrand factor (VWF:Ag), and d‐dimer levels. At three sessions with a washout period in between, blood was taken from 12 healthy male individu…

medicine.medical_specialtymedicine.drug_mechanism_of_actionFactor Xa Inhibitorapixabanfactor Xa inhibitors030204 cardiovascular system & hematologyTreatment resultsFibrinogenGastroenterology03 medical and health sciences0302 clinical medicineVon Willebrand factorInternal medicinecoagulantsMedicinerivaroxabanBlood coagulation testRivaroxabanbiologybusiness.industryBrief Reportblood coagulation testsrisk assessmentHematologyCoagulation030220 oncology & carcinogenesisbiology.proteinApixabanbusinessOriginal Articles: Thrombosismedicine.drug
researchProduct

2020

Background. Anticoagulant therapy, the cornerstone treatment in acute venous thromboembolism (VTE), strongly impacts thrombin generation (TG). Until now, the appearance of the TG curve in platelet rich plasma (PRP) from patients with acute VTE has not been investigated. Methods. We analyzed the shape of TG curves measured in PARP of 180 acute VTE patients. Results. Normal shape of TG curves was observed in 110 patients, 50 patients showed no TG and 20 patients showed biphasic TG curve. The linear regression analysis, adjusted for age, sex, VTE clinical phenotypes and therapy showed that the appearance of biphasic curves is significantly associated with female sex, presence of cancer and the…

medicine.medical_specialtymedicine.drug_mechanism_of_actionbusiness.industryFactor Xa InhibitorCancerGeneral Medicinemedicine.diseaseGastroenterologyThrombin generationPlatelet-rich plasmaInternal medicinemedicineClinical significanceCurve shapePlateletcardiovascular diseasesbusinessVenous thromboembolismJournal of Clinical Medicine
researchProduct

Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants.

2018

BACKGROUND AND PURPOSE Whereas intravenous thrombolysis (IVT) is allowed for acute ischaemic stroke in patients on vitamin K antagonists with international normalized ratio ≤1.7, there are no similar recommendations for patients on direct oral anticoagulants (DOACs), notably due to the lack of coagulation tests to assess the therapeutic effects. Although the literature is scarce, consisting of small case series and retrospective studies, considering the frequency of this situation the French Vascular Neurology Society and the French Study Group on Haemostasis and Thrombosis have worked on a joint position paper to provide a practical position regarding the emergency management of ischaemic …

medicine.medical_specialtymedicine.medical_treatmentAdministration Oral030204 cardiovascular system & hematologyAntithrombinsDabigatranBrain Ischemia03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRivaroxabanAtrial FibrillationCoagulation testingMedicineHumansThrombolytic TherapyStrokeRetrospective StudiesProthrombin timeRivaroxabanmedicine.diagnostic_testbusiness.industryAnticoagulantsIdarucizumabThrombolysismedicine.diseaseDabigatranStrokeNeurologyEmergency medicineAdministration IntravenousNeurology (clinical)Blood Coagulation Testsbusiness030217 neurology & neurosurgeryPartial thromboplastin timemedicine.drugFactor Xa InhibitorsEuropean journal of neurology
researchProduct

Cytokine components and mucosal immunity in the oviduct of Xenopus laevis (amphibia, pipidae)

2011

Abstract Most studies on the mucosal immunity in female reproductive tissues have been performed in mammals. In all species, apart from their reproductive strategies, immunity in the genital mucosa is required to defend the host against luminal pathogens. In this study we investigated the role of the innate immunity of the oviductal mucosa of Xenopus laevis , an amphibian characterized by external fertilization. In particular we examined the expression and localization of Interleukin-1β (IL1B), Macrophage migration inhibitory factor (MIF) and Interleukin-1 receptor type 1 (IL1R1) in different oviductal portions including an upper glandular region, an intermediate and a lower aglandular regi…

medicine.medical_treatmentImmunologyInterleukin-1betaXenopus laeviXenopusOviductsXenopus laevisEndocrinologyImmunitymedicineAnimalsImmunity MucosalMacrophage Migration-Inhibitory FactorsReceptors Interleukin-1 Type IInnate immune systembiologybiology.organism_classificationImmunohistochemistryMolecular biologyEpitheliumFemale reproductive tissues; Interleukin-1; Interleukin-1 receptor type 1; Macrophage migration inhibitory factor Xenopus laevismedicine.anatomical_structureCytokineCytokinesOviductImmunohistochemistryFemaleAnimal Science and ZoologyMacrophage migration inhibitory factorGeneral and Comparative Endocrinology
researchProduct